|
Gene: SPAG17 |
Gene summary for SPAG17 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPAG17 | Gene ID | 200162 |
Gene name | sperm associated antigen 17 | |
Gene Alias | CT143 | |
Cytomap | 1p12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q6Q759 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200162 | SPAG17 | PTC06 | Human | Thyroid | PTC | 4.17e-03 | 1.36e-01 | 0.2057 |
200162 | SPAG17 | ATC13 | Human | Thyroid | ATC | 1.50e-35 | 6.29e-01 | 0.34 |
200162 | SPAG17 | ATC5 | Human | Thyroid | ATC | 1.46e-39 | 6.82e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG17 | SNV | Missense_Mutation | novel | c.6293T>A | p.Val2098Glu | p.V2098E | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-85-8287-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.5413G>A | p.Val1805Ile | p.V1805I | Q6Q759 | protein_coding | tolerated(0.29) | benign(0.011) | TCGA-85-8352-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
SPAG17 | SNV | Missense_Mutation | novel | c.4264N>C | p.Ala1422Pro | p.A1422P | Q6Q759 | protein_coding | deleterious(0) | possibly_damaging(0.779) | TCGA-90-7769-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.3493G>A | p.Val1165Met | p.V1165M | Q6Q759 | protein_coding | deleterious(0.03) | possibly_damaging(0.73) | TCGA-96-8170-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | SNV | Missense_Mutation | novel | c.5913N>A | p.Ser1971Arg | p.S1971R | Q6Q759 | protein_coding | tolerated(0.47) | benign(0) | TCGA-NC-A5HG-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | CR |
SPAG17 | SNV | Missense_Mutation | rs774289091 | c.671N>C | p.Ile224Thr | p.I224T | Q6Q759 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-NC-A5HN-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SPAG17 | insertion | Nonsense_Mutation | novel | c.4973_4974insGAAAAAGTAAGA | p.Ser1658delinsArgLysLysTerAsp | p.S1658delinsRKK*D | Q6Q759 | protein_coding | TCGA-55-8616-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SPAG17 | deletion | Frame_Shift_Del | c.3193delN | p.Val1065Ter | p.V1065* | Q6Q759 | protein_coding | TCGA-86-7955-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | PD | |||
SPAG17 | insertion | Frame_Shift_Ins | novel | c.3132_3133insG | p.Gln1045AlafsTer3 | p.Q1045Afs*3 | Q6Q759 | protein_coding | TCGA-NJ-A4YF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SPAG17 | insertion | Frame_Shift_Ins | novel | c.3444_3445insGCCG | p.Pro1149AlafsTer3 | p.P1149Afs*3 | Q6Q759 | protein_coding | TCGA-22-4591-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | gemzar | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |